Clinical Trial

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

Study acronym: ACROSS-TROP2
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 19, 2024 (before its estimated February 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open-label, single arm, non-randomized, multicenter phase II study for the identification of predictive biomarkers of sacituzumab govitecan benefit and the understanding of key resistance mechanisms in HR+/HER2- advanced/metastatic breast cancer patients
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-23.
Status change: Not Yet Recruiting → Recruiting 2024-07-18
Trial Details
NCT Number NCT06236269
Lead Sponsor SOLTI Breast Cancer Research Group
Conditions Breast Cancer Stage IV
Enrollment 50 participants
Start Date 2024-03-15
Primary Completion 2026-02-20 (estimated)
Study Completion 2027-02-20 (estimated)
Updated on ClinicalTrials.gov 2024-07-19